{Reference Type}: Journal Article
{Title}: Management of circumscribed choroidal hemangioma at a tertiary care center.
{Author}: Koç İ;Yücel Gençoğlu A;Yücekul B;Deliktaş Ö;Öztürk E;Kiratli H;
{Journal}: Int Ophthalmol
{Volume}: 44
{Issue}: 1
{Year}: 2024 Jul 2
{Factor}: 2.029
{DOI}: 10.1007/s10792-024-03238-y
{Abstract}: <B>OBJECTIVE: </B>To review long-term outcomes of circumscribed choroidal hemangioma (CCH).<BR><B>METHODS: </B>Hospital charts of all CCH cases diagnosed from 2008 to 2019 were retrospectively reviewed.<BR><B>RESULTS: </B>All 172 patients were managed with either observation, transpupillary thermotherapy, argon laser photocoagulation, photodynamic therapy, plaque brachytherapy or stereotactic radiosurgery. The most common 3 modes of management were clinical observation (30.2%), transpupillary thermotherapy (52.9%) and argon laser photocoagulation (8.7%). Median follow-up time was 10 months (range: 3, 160). Anatomical outcomes were stable in 87.1% of observation group and improved in 60.5% of thermotherapy group. Quantified optical coherence tomography angiography findings showed statistical differences in vascular and perfusion densities in fellow eyes of hemangioma patients.<BR><B>CONCLUSIONS: </B>Circumscribed choroidal hemangioma can be treated in various ways. Transpupillary thermotherapy is an anatomically effective treatment in selected cases. The diagnosis of CCH may have vascular implications in fellow eyes of the patients.